← Back to Screener
Fulgent Genetics, Inc. Common Stock (FLGT)
Price$18.09
Value ScoreC
Growth ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-52.90%
Price vs S&P 500 (4W)23.41%
VGM Score36.21
Market Capitalization$519.16M
All Metrics
P/CF (Annual)21.90x
Book Value / Share (Quarterly)$36.39
P/TBV (Annual)0.83x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-19.52%
Cash Flow / Share (Quarterly)$-3.92
Price vs S&P 500 (YTD)-41.88%
Gross Margin (TTM)38.71%
Net Profit Margin (TTM)-23.04%
EPS (TTM)$-2.40
10-Day Avg Trading Volume0.55M
EPS Excl Extra (TTM)$-2.40
Revenue Growth (5Y)-5.21%
EPS (Annual)$-1.97
ROI (Annual)-5.43%
Gross Margin (Annual)40.56%
Net Profit Margin (5Y Avg)-3.51%
Cash / Share (Quarterly)$9.58
Revenue Growth QoQ (YoY)-3.16%
ROA (Last FY)-4.99%
Revenue Growth TTM (YoY)9.54%
EBITD / Share (TTM)$-3.50
ROE (5Y Avg)6.23%
Operating Margin (TTM)-36.16%
Cash Flow / Share (Annual)$-4.00
P/B Ratio0.49x
P/B Ratio (Quarterly)0.45x
Net Income / Employee (Annual)$-46,000
EV / Revenue (TTM)1.55x
Net Interest Coverage (TTM)0.17x
ROA (TTM)-6.17%
EV / EBITDA (TTM)2.69x
EPS Incl Extra (Annual)$-1.97
Current Ratio (Annual)6.48x
Quick Ratio (Quarterly)4.03x
3-Month Avg Trading Volume0.55M
52-Week Price Return-11.98%
EV / Free Cash Flow (Annual)2.11x
Revenue / Employee (TTM)$243,600
Tangible BV / Share (Quarterly)$31.05
P/S Ratio (Annual)1.61x
Asset Turnover (Annual)0.27x
52-Week High$31.04
Operating Margin (5Y Avg)-6.32%
EPS Excl Extra (Annual)$-1.97
CapEx CAGR (5Y)-8.45%
Tangible BV CAGR (5Y)78.18%
26-Week Price Return-36.97%
Quick Ratio (Annual)5.16x
13-Week Price Return-26.74%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.31x
Enterprise Value$497.99M
Revenue / Share Growth (5Y)-9.74%
Asset Turnover (TTM)0.27x
Book Value / Share Growth (5Y)12.12%
Revenue / Employee (Annual)$245,400
Pretax Margin (Annual)-21.70%
Cash / Share (Annual)$10.81
3-Month Return Std Dev89.83%
Gross Margin (5Y Avg)50.41%
Net Income / Employee (TTM)$-56,100
ROE (Last FY)-5.44%
EPS Basic Excl Extra (Annual)$-1.97
P/FCF (TTM)74.68x
Receivables Turnover (TTM)4.55x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.40
Receivables Turnover (Annual)4.20x
ROI (TTM)-6.69%
P/S Ratio (TTM)1.62x
Pretax Margin (5Y Avg)-0.45%
Revenue / Share (Annual)$10.48
Tangible BV / Share (Annual)$31.49
Forward P/E88.46x
Price vs S&P 500 (52W)-40.19%
Year-to-Date Return-30.95%
5-Day Price Return6.02%
EPS Normalized (Annual)$-1.97
ROA (5Y Avg)5.59%
Net Profit Margin (Annual)-18.75%
Month-to-Date Return19.42%
Cash Flow / Share (TTM)$-1.20
EBITD / Share (Annual)$-3.02
Operating Margin (Annual)-31.31%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)302.87x
ROI (5Y Avg)6.03%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.40
P/TBV (Quarterly)0.53x
P/B Ratio (Annual)0.73x
Pretax Margin (TTM)-26.31%
Book Value / Share (Annual)$35.78
Price vs S&P 500 (13W)-36.48%
Beta0.93x
P/FCF (Annual)108.25x
Revenue / Share (TTM)$10.37
ROE (TTM)-6.70%
52-Week Low$13.46
vGradeC
gGradeD
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.36est. -0.11
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Health Services(28)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FLGTFulgent Genetics, Inc. Common Stock | C | D | D | $18.09 |
| NTRANatera, Inc. Common Stock | F | A | B | $218.81 |
| DGXQuest Diagnostics Inc. | C | D | C | $192.20 |
| LHLabcorp Holdings Inc. | C | D | C | $256.87 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $129.14 |
| CELCCelcuity Inc. Common Stock | — | — | B | $122.96 |
| CAICaris Life Sciences, Inc. Common Stock | F | F | C | $16.45 |
| RDNTRadNet, Inc. Common Stock | D | C | D | $52.89 |
| VCYTVeracyte, Inc. | D | A | B | $48.18 |
| GRALGRAIL, Inc. Common Stock | D | A | B | $64.40 |
About
Fulgent Genetics is a genetic testing company providing physicians with diagnostic laboratory services and clinical interpretation to guide patient treatment. The company's core laboratory services segment, which generates the majority of revenue, offers technical testing and professional interpretation by licensed physicians. The company also operates a therapeutic development business focused on developing cancer drug candidates, with operations primarily in the United States and select international markets.